Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System
Axonics sets recharge-free neuromodulation benchmark with FDA labeling for 15+ years of functional life at typical stimulation parameters and 20+ years at lower energy settings IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the […]